Epitalon and Vilon Interaction: Synergistic | Peptide Database

The classic PCT SERM. Tamoxifen blocks estrogen negative feedback at the hypothalamus and pituitary, driving LH and FSH elevation to restart endogenous testosterone production after suppression from anabolic steroids or exogenous testosterone. Accelerates the return of serum testosterone to baseline levels following cycle cessation, reducing the duration of the hypogonadal window and associated symptoms such as fatigue, low libido, and muscle loss. Blocks estrogen receptor activation in breast tissue during aromatizable steroid cycles, preventing the development of gynecomastia without reducing systemic estrogen levels. Can reduce early-stage gynecomastia symptoms (tenderness, lump formation) by competitively blocking estrogen at the breast tissue receptor level. Less effective once fibrotic tissue has formed. FDA-approved for adjuvant treatment of estrogen receptor-positive breast cancer in both pre- and postmenopausal women. Reduces recurrence rates and mortality when used for 5-10 years following primary treatment. FDA-approved for chemoprevention in women at high risk of developing breast cancer. The NSABP P-1 trial demonstrated a 49% reduction in invasive breast cancer incidence.

Join others researching Trazodone — share findings, ask questions, and learn from real experiences Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes. Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.